Stevens E, Jacknin L, Robbins PF. Kawakami Y, El-Gamil M, Rosenberg SA, and Yannelli J. The generation of tumor-specific cytotoxic T lymphocytes from melanoma patients using peripheral blood stimulated with allogeneic melanoma tumor cell lines: Fine specificity and MART-1 melanoma antigen recognition. J Immunol.154(2):762-771.1995 Jan
Sanda MG, Restifo NP, Walsh J, Kawakami Y, Nelson WG, Pardoll DM and Simons JW. Molecular characterization of defective antigen processing in human prostate cancer.J Natl Cancer Inst.87(4):280-285.1995 Feb
Wang R, Robbins PF, Kawakami Y, Kang X, and Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31 restricted tumor-infiltrating lymphocytes. J Exp Med.181(2):799-804.1995 Feb
Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, and Rosenberg SA.Inductrion of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with the human melanoma antigen MART-1 peptide. J Immunol.154(5):2257-2265.1995 Mar
Kawakami Y, Eliyafu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, and Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigens gp100 by tumor infiltrating T-lymphocytes associated with in vivo tumor regression. J Immunol.154(8):3961-3968.1995 Apr
Cole DJ, Weil DP, Shilyansky J, Custer M, Kawakami Y, Rosenberg SA and Nishimura MI. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res.55(4):748-752.1995 Feb
Robbins PF, El-Gamil M, Li Y, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y and Rosenberg SA. Cloning of new gene encoding antigen recognized by HLA-A24 restricted tumor infiltrating lymphocytes. J.Immunol. 154:5944-5950, 1995..154(11):5944-5950.1995 Jun
Bakker AB, Schreurs MW, Tafazzul G, de Boer AJ, Kawakami Y, Adema GJ and Figdor CG. Identification of a novel peptide derived from the melanocyte specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1 restricted anti-melanoma CTL line. Int. J. Cancer. 62:97-102, 1995. .62(1):97-102.1995 Jul
Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA and Marincola FM. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res.55(14):3149-3157.1995 Jul
Kang X, Kawakami Y, Wang R, El-Gamil M, Yannelli JR, Rosenberg SA, and RobbinsPF.Identification of a tyrosinase epitope recognized by HLA-A24restricted tumor-infiltrating lymphocytes. J Immunol.155(3):1343-1348.1995 Aug
Salgaller M, Marincola F, Rivoltini L, Kawakami Y and Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by antigen specific peripheral blood lymphocytes stimulated with synthetic peptides. Cancer Res.55(21):4972-4979.1995 Nov
Yannelli JR, McConnell S, Parker L, Nishimura M, Robbins PF, Yang J and Kawakami Y. Melanoma tumor infiltrating lymphocytes derived from four distinct anatomic sites obtained from a single patient: Comparison of functional reactivity and melanoma antigen recognition. J Immunother.18(4):263-271.1995 Nov
Kawakami Y, and Robbins PF: Biology of tumor antigens. Genes coding for tumor antigens recognized by T-cells. in “Biologic therapy of cancer” V. DeVita, S. Hellman, S.A.Rosenberg, eds. J.B.Lippincott Co., Philadelphia:53-64.1995